Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
about
Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2Cancer-treatment-induced neurotoxicity--focus on newer treatmentsPersonalised cancer medicineComparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic usePharmacogenomics: the promise of personalized medicineAntibody-targeted radiation cancer therapyReverse phase protein microarrays advance to use in clinical trialsOxidative Stress Mediates the Antiproliferative Effects of Nelfinavir in Breast Cancer CellsRemoving T-cell epitopes with computational protein design.Recombinant antibodies: a novel approach to cancer diagnosis and therapy.Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.Phage display in molecular imaging and diagnosis of cancer.Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.Construction, MD simulation, and hydrodynamic validation of an all-atom model of a monoclonal IgG antibody.Generation of high-affinity fully human anti-interleukin-8 antibodies from its cDNA by two-hybrid screening and affinity maturation in yeastDetermination of primary structure and microheterogeneity of a beta-amyloid plaque-specific antibody using high-performance LC-tandem mass spectrometry.Anticancer drug targets: growth factors and growth factor signaling.Pharmacogenomics. Interview by Clare ThompsonT cell coinhibition and immunotherapy in human breast cancerDrug delivery to brain tumours: challenges and progress.HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosisTargeting lymphatic vessel functions through tyrosine kinases.Genetically engineered rodent models of mammary gland carcinogenesis: an overview.Antibody-DM1 conjugates as cancer therapeutics.Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.Novel nanoimaging approach: antibodious polymeric nanolabel for intracellular alpha-fetoprotein targeted monitoring.Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors.Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.A two-step toward personalized therapies for prostate cancerPharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling.Identification of anti-CD98 antibody mimotopes for inducing antibodies with antitumor activity by mimotope immunization.Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists.p185, an immunodominant epitope, is an autoantigen mimotope.HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.α-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration.
P2860
Q21134904-89BECCFF-1791-4B5B-9B33-2BDC273B21E7Q26782604-8C66FF27-9F5E-4262-975F-3FE0B451006DQ26991908-34AB0BC4-82C5-4E08-8FC2-724379ED0373Q28140514-48903E42-3D4F-4A2F-A5F5-48395325D9ADQ28210286-74A13FF1-E9E0-44E4-9DD6-23ACBEA34C4FQ28264580-8E07CD24-B3AF-4F7E-9B43-821B22C77CE3Q28384553-78EFCD98-C5CB-4878-B814-DE51DE5A7CB7Q28550200-E9C4EF27-71BC-4F85-ACCF-747BD0790C78Q30362724-F7C2E2E9-3863-414C-A733-DE6D53963C02Q33181384-FC56C1BC-D5F0-442B-9E66-603E93E5683AQ33410392-7A42A909-1E45-465A-AD21-7D5A44FE0493Q33517907-FF4BE72C-D3D8-45B5-9E0E-C0A297F6EE5EQ33532734-AA044054-A737-4CC5-A2D9-189327268224Q33607045-E5DB0EFC-2CC4-46E0-BC47-962524BB7E89Q33648617-FBD64108-B2F6-44AA-B39C-7C13722C948BQ33662280-8F73C6BA-D7F4-4960-84EE-8C96EACC1741Q33743933-F6580B4A-7AE8-4522-930D-CC9BDFC131A6Q33808352-6D7B9D5D-6886-4231-B186-ECC4D8C35FAAQ33821420-58048458-5FE2-47BC-B40A-1ACFCC1BD9B2Q33936154-6748FE93-11FB-4F6B-9D05-72AC2C0A5650Q33997439-C43AA9EC-3829-423D-9F38-FF3005196667Q34029209-0AB7C947-511E-4DF5-965A-DA2FBBBAAFA5Q34078275-D53257BF-5A20-42E9-BF40-8410501AAFD2Q34160186-98E58A2F-EAF2-46F0-916E-246EAF35FF49Q34177359-FEC5396B-A0B0-4A42-B9E1-CE7EA4EC0080Q34348403-8DF9260B-5DFA-45D8-8939-8A9578281B76Q34435827-CD7DE1AE-A682-4D88-B2FA-B720BA368394Q34504799-F931688A-F534-4ED2-B684-94BDA3A959B5Q34535370-5D7CA282-B825-4688-A15E-273F64B0688BQ34574834-0223CCBF-7D9A-444C-9433-68E7294AA6D3Q34651534-A39B0CEA-168A-46F2-B204-AFC22497630DQ34778047-EEF51361-6B62-4D8F-9842-47922B23E582Q34952878-2CA2E11F-56EA-4ECE-B70A-EB6AC85CC47EQ34978420-2B7FDFE0-AA58-4B89-802F-DBD575401096Q35021035-717E35EE-E971-41C3-962D-D1C8A73A6B0DQ35051389-B9D63654-DC4B-4CC9-A3D4-51069D8D1155Q35062566-56FCF687-DA2B-41B2-A1A7-CC8301630ECAQ35110970-0C72E920-2682-481F-9DF9-6FB643473608Q35111575-AD21B6DC-F266-4018-9DB1-0D86B9EE8877Q35151075-01DEDA04-8DA0-4AA0-BF76-4680228658A9
P2860
Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Trastuzumab, a recombinant DNA ...... t of metastatic breast cancer.
@ast
Trastuzumab, a recombinant DNA ...... t of metastatic breast cancer.
@en
type
label
Trastuzumab, a recombinant DNA ...... t of metastatic breast cancer.
@ast
Trastuzumab, a recombinant DNA ...... t of metastatic breast cancer.
@en
prefLabel
Trastuzumab, a recombinant DNA ...... t of metastatic breast cancer.
@ast
Trastuzumab, a recombinant DNA ...... t of metastatic breast cancer.
@en
P1476
Trastuzumab, a recombinant DNA ...... t of metastatic breast cancer.
@en
P2093
M M Goldenberg
P304
P356
10.1016/S0149-2918(00)88288-0
P577
1999-02-01T00:00:00Z